More on ALC
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $70.63 |
|
|||
| Open | $70.16 | ||||
| 52 Wk High | $14.66 | ||||
| 52 Wk Low | $6.93 | ||||
| Day High | $70.46 | ||||
| Day Low | $69.54 | ||||
| P/E | N/A | ||||
| EPS | $-1.75 | ||||
| Volume | 2,592,437 | ||||
- Alcon acquires Neurotech for $550M, adding rare eye disease drug
- Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
- Algoma Central Corporation to Release Third Quarter 2026 Results on November 6, 2026; Announces Preliminary Results
- FDA approves Alcon eye drops for up to 12 hours of redness relief
- FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
- Increasing unusual option volume: JBS CCC AIPO INDA CMBT ERIC ALC
- Algoma Central Corporation Increases Quarterly Dividend and Declares Special Dividend
- Barclays Starts Alcon Inc. (ALC) at Equalweight
- Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief
- Alcon launches Unity M ophthalmic microscope in U.S. and Japan
Entities mentioned with ALC
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Dividend | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Alcon Acquired by Novartis | View Related Stories »
- FDA | View Related Stories »
- Show More...
